Skip to main content
Premium Trial:

Request an Annual Quote

LifeSpan Signs Aventis as Subscriber to GPCR Database

NEW YORK, Oct. 9 – LifeSpan BioSciences of Seattle said Tuesday it had signed Aventis Pharma as its sixth subscriber to its G protein-coupled receptors database.

The database Lifespan will provide to Aventis of Strasbourg, France, includes information on non-olfactory GPCRs. The database, which is designed to help users to identify and prioritize potential drug targets, was designed to be used by Aventis’ branches in the US, Germany, and France.

"We are now mapping the top 320 GPCRs of potential therapeutic interest,” Joseph Brown, CEO of LifeSpan BioSciences, said in a statement. 

GPCRs comprise a family of cell-surface molecules that act as receptors for many biologically active compounds and pharmaceuticals. 

LifeSpan’s other subscribers are Pfizer, Merck, Bristol-Myers Squibb, Novartis Research Foundation, and Sanofi-Snythelabo.

Financial terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.